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Abstract
Background: Clinical outcomes in neuromyelitis optica spectrum disorders (NMOSD) vary across
different regions.
Objective: To describe clinical profiles in Japanese and German NMOSD patients.
Methods: Medical records of aquaporin-4-immunoglobulin G (AQP4-IgG) positive NMOSD patients
from Japan (n¼ 54) and Germany (n¼ 38) were retrospectively analyzed.
Results: The disability status was similar between both cohorts, although Japanese patients had a longer
disease duration (13.3 11.1 vs. 8.1 6.9 years, p¼ 0.018) but similar relapse rates. Optic neuritis and
myelitis were the most frequent attacks in both cohorts. Brain attacks occurred more frequently in
Japanese patients (40.7% vs. 15.8%, p¼ 0.020). The time from disease onset (median [interquartile
range] 2.3 [0.3-10.1] vs. 0.6 [0.2-1.9] years, p¼ 0.009) and the number of attacks (2.5 [1-7] vs.
2 [1-3], p¼ 0.047) until start of the first immunotherapy were higher in the Japanese cohort.
Rituximab was the most common drug in the German cohort (52.6%) and not given in the Japanese
cohort (p< 0.001), where oral prednisolone was the most common drug (92.6% vs. 15.8%, p< 0.001).
The frequency of autoimmune comorbidities was higher in the German cohort (39.5% vs. 18.5%,
p¼ 0.047).
Conclusion: Compared with Japanese NMOSD patients, German patients presented with similar dis-
ability despite shorter disease duration and earlier and more frequent immunosuppressive therapy.
Keywords: Anti-aquaporin 4 antibodies, autoimmune diseases, ethnicity, immunotherapy, neuromyelitis
optica spectrum disorders
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Introduction
Neuromyelitis optica spectrums disorders (NMOSD)
are a group of autoimmune conditions of the CNS
that share an overlapping clinical phenotype includ-
ing optic neuritis (ON), longitudinally extensive
transverse myelitis (LETM), encephalitis, and brain-
stem involvement.1,2 In most cases, attacks occur
recurrently and clinical symptoms are severe, recov-
er only partially, and lead to chronic disability.2
Consequently, patients suffer from visual deficits
up to blindness, sensorimotor dysfunction, sphincter
and bladder disturbances, pain, depression, fatigue
and cognitive impairment, leading to a significantly
reduced quality of life.3–8
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Disease remission is rare and symptomatic treatment
can be difficult.2,9 About 80% of patients with a
clinical phenotype of NMOSD have serum immuno-
globulin G antibodies against aquaporin-4 (AQP4-
IgG), a water channel expressed in the astrocytic
end-feet at the blood-brain-barrier.10 Causing astro-
cytopathy with secondary demyelination, AQP4-IgG
are of pathogenic relevance.1
In a subgroup of AQP4-IgG negative patients with a
clinical phenotype of NMOSD, antibodies targeting
myelin oligodendrocyte glycoprotein (MOG) have
been detected.2,11 The present study focuses only
on AQP4-IgG-positive NMOSD. Data on Anti-
MOG antibody-associated disorders from the same
cohorts have recently been published separately.12
In some frequent autoimmune disorders like MS,
epidemiology and disease presentation differ sub-
stantially between different regions of the world.13
In NMOSD, data on prevalence and incidence are
scarce. A few reports suggest that its global distri-
bution is relatively similar,14 while some studies
reported that NMOSD prevalence is higher in non-
white than in white populations15,16 and higher in
individuals with Asian ancestry than in other ethnic-
ities.17 Asian, Afro-American, Afro-Caribbean, and
Afro-European patients have a lower age of onset
than Caucasian patients, a higher prevalence of
brain attacks and more frequent brain abnormalities
on MRI.13,18–20 Clinically, Afro-American and Afro-
European patients are more likely to have severe
attacks, a higher likelihood of visual disability13,18
and worse motor deficits than Asian and Caucasian
patients.18,21 Compared to Asian patients, Caucasian
and Afro-Caribbean patients have a younger age at
disease onset, worse onset attacks with a higher risk
of visual impairment and a more severe disease
course with a higher relapse frequency and greater
disability, despite earlier immunosuppression.13
The aim of this study was to compare demographic
and clinical features as well as treatment strategies




Data were obtained from adult AQP4-IgG-positive
patients with NMOSD treated at outpatient and inpa-
tient clinics at Chiba University Hospital, Japan, and
from an ongoing observational study following
patients with AQP4-IgG-positive NMOSD and
related disorders at Charite - Universit€atsmedizin
Berlin, Germany. All patients gave written informed
consent to study participation. The study was
approved by the Ethics Committees of the partici-
pating centers. Patients were included at any time
during their disease course. All data were acquired
during remission.
Databases at the respective study centers were
screened for eligibility of AQP4-IgG-positive
patients. Inclusion criteria for the study was a diag-
nosis of AQP4-IgG-positive NMOSD according to
the 2015 international consensus diagnostic criteria
for NMOSD.1 Serostatus was tested in Germany
using a cell-based assay (CBA) (Euroimmun,
Lübeck, Germany) and in Japan using flow
cytometry-CBA, as described previously.22
Although the methodology in the centers was differ-
ent, the high specificity and sensitivity of both meth-
ods have already been demonstrated.23 Of note, all
patients included tested negative for MOG-IgG.
Patient data assessment
All data was retrospectively analyzed. We studied
demographics (sex, ethnicity), age at disease onset,
number and type of attacks (categorized as ON,
transverse myelitis, brainstem, area postrema, cere-
bral and mixed attacks), disease duration at last
follow-up, attack treatment, previous and current
immunotherapy, annualized relapse rate (ARR),
ARR before any treatment and during current treat-
ment, Expanded Disability Status Scale (EDSS)
score including functional system scores (FSS) at
last follow-up, EDSS increase per attack, recovery
from first attack, first ON and first myelitis, concom-
itant autoimmune diseases, presence/absence of
CSF-specific oligoclonal bands and presence/
absence of long spinal cord lesions at any time
during the disease course, as well as persistent mye-
litis, brainstem/area postrema and cerebral lesions on
1.5-Tesla (Japan) and 3-Tesla (Germany) MRI at last
follow-up. As all data were acquired outside of acute
attacks, no contrast agent was given during MRI.
Statistics
Statistical analysis was performed in R version 3.4.4
with R Studio Version 1.1.442 (R Core Team
(2013). R: A language and environment for statisti-
cal computing. R Foundation for Statistical
Computing, Vienna, Austria, www.r-project.org/).
Continuous variables are given as meanstandard
deviation (SD) and were compared with t-tests in
the case of a normal distribution. Non-
parametric data are presented as median and inter-
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Wilcoxon-Mann-Whitney U test. Categorical data
was tested using Pearson’s Chi-Square test.
Kaplan-Meier curves with cox proportional hazard
models were used for estimating the time to the
second attack. For the latter analysis, we included
only patients with a follow-up period of at least two
years, avoiding bias from patients without a second
attack due to short follow-up. Patients were censored
after seven years due to a low number of cases with a
longer follow-up. P-values 0.05 were considered to
indicate statistical significance. Due to the
exploratory nature of this study no adjustments for
multiple testing were made.
Results
Demographics and clinical characteristics
We included 92 AQP4-IgG-positive NMOSD
patients from Germany (n¼ 38, Caucasian) and
Japan (n¼ 54, East-Asian). One patient from
Germany had to be excluded because of incomplete
Table 1. Demographic and clinical characteristics of AQP4-IgG-positive Japanese and German NMOSD






Age at last follow-up, years: mean SD 50.61 14.00 55.30 13.13 0.104
Sex: n female/male (female %) 35/3 (92.1%) 48/6 (88.9%) 0.877
Age at disease onset, years: mean SD 42.50 15.32 41.96 14.96 0.867
Early/late disease onset: n (%) 0.858
<30 years 7 (18.4%) 12 (22.2%)
30–50 years 13 (34.2%) 16 (29.6%)
>50 years 18 (47.4%) 26 (48.1%)
Disease duration at last follow-up, years: mean SD 8.11 6.90 13.33 11.08 0.018
EDSS at last follow-up: median [IQR] 4 [2.12, 5.25] 4.00 [2.00, 5.75] 0.784
Visual FSS: median [IQR] 1.00 [0.00, 3.00] 1.00 [1.00, 2.00] 0.807
Brainstem FSS: median [IQR] 0.00 [0.00, 1.00] 0.00 [0.00, 0.00] <0.001
Pyramidal FSS: median [IQR] 1.00 [0.00, 3.00] 0.00 [0.00, 0.00] <0.001
Cerebellar FSS: median [IQR] 1.00 [0.00, 2.00] 2.00 [0.00, 3.00] 0.155
Sensory FSS: median [IQR] 2.00 [1.00, 3.00] 0.50 [0.00, 2.00] 0.001
Bowel and bladder FSS: median [IQR] 1.00 [0.00, 2.00] 2.00 [0.00, 5.00] 0.037
Cerebral FSS: median [IQR] 0.50 [0.00, 1.00] 0.00 [0.00, 0.00] <0.001
Ambulation FSS: median [IQR] 4.50 [0.00, 4.88] 1.00 [0.00, 5.25] 0.669
Severe disability at last follow-up: n (%) 8 (21.1%) 14 (25.9%) 0.771
EDSS increase per attack: median [IQR] 0.95 [0.67, 1.56] 0.63 [0.48, 1.24] 0.059
CSF-specific oligoclonal bands: n (%) 6/25(19.4%) 8/27 (22.9%) 0.964
Autoimmune comorbidities: n (%) 15 (39.5%) 10 (18.5%) 0.047
– Sjoergen syndrome: n (%) 3 (7.9%) 6 (11.1%) 0.877
– Hashimoto disease: n (%) 5 (13.2%) 3 (5.6%) 0.369
– Rheumatoid arthritis: n (%) 1 (2.6%) 1 (1.9%) >0.999
– Myasthenia gravis: n (%) 3 (7.9%) 1 (1.9%) 0.379
– Systemic lupus erythematosus: n (%) 6 (15.8%) 0 (0.0%) 0.010
– Raynaud’s syndrome: n (%) 1 (2.6%) 0 (0.0%) 0.859
– Mixed connective tissue disease: n (%) 2 (5.3%) 0 (0.0%) 0.328
– Secondary antiphospholipid syndrome: n (%) 1 (2.6%) 0 (0.0%) 0.859
AQP4-IgG: Aquaporin 4-immunoglobulin G; EDSS: expanded disability status scale; FSS: functional system score;
IQR: interquartile range; n¼ number; NMOSD: neuromyelitis optica spectrum disorders, SD: standard deviation.
Note that these group comparisons were performed using t-test for current age, age at disease onset, and disease
duration, Chi-square-test for categorial variables, severe disability at last follow-up (defined as an EDSS 6), and
Wilcoxon-Mann-Whitney test for EDSS and functional system scores and EDSS increase per attack. Significant p-
values are indicated in bold.
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clinical data. Table 1 provides an overview of the
demographic and clinical findings. There were no
differences regarding sex distribution, age at disease
onset or age at last follow-up between the groups. A
histogram analysis revealed two peaks of disease
onset in both cohorts: 1) around 20 years of age, 2)
around 40 years of age (Figure 1). There was no
difference regarding disease onset in summer
(April to September) or winter (October to March)
between both cohorts (p¼ 0.324), nor between onset
in summer (Germany: p¼ 0.447, Japan: p¼ 0.574)
or winter (Germany t: p¼ 0.553, Japan: p¼ 0.426)
within the cohorts. Nine patients from Japan and
four patients from Germany had only one attack at
time of last follow-up. The frequency of autoim-
mune comorbidities was higher in the German
cohort (p¼ 0.047). Six German patients (15.8%)
but no Japanese patient (p¼ 0.010) had concomitant
systemic lupus erythematosus (SLE) (Table 1).
Disease course
At the time of assessment, Japanese patients had a
longer disease duration than German patients
(meanSD: 13.33 11.08 vs. 8.11 6.90,
p¼ 0.018), although the number of attacks was sim-
ilar (median [IQR]: 3.00 [2.00, 5.00] vs. 5.00 [2.00,
9.75], p¼ 0.115).
Table 2 provides details about the disease course and
the type of attacks. A comparable number of patients
had experienced at least one myelitis. There was no
difference between Japanese and German patients in
the frequency of ON. However, brain attacks -
including area postrema, brainstem and cerebrum -
were more frequent in Japanese patients (p¼ 0.020).
Most brain attacks were area postrema and/or brain-
stem attacks (German cohort n¼ 8 (100%), Japanese
cohort n¼ 22 (61.1%)). Cerebral attacks occurred
only in the Japanese cohort (n¼ 14 (38.9%)).
ARR did not differ between both groups. Kaplan-
Meier statistics with Cox regression showed that
there was no significant difference in the risk for a
second attack, though with a trend for a lower risk in
the Japanese cohort cohort (Hazard ratio ¼0.461,
confidence interval (CI) 0.195-1.09, p¼ 0.078)
(Figure 2). EDSS at last follow-up did not differ
between both groups (4.00 [2.00, 5.75] (Japan) vs.
4.00 [2.12, 5.25] (Germany), p¼ 0.784). However,
brainstem, pyramidal, sensory, and cerebral FSS
were lower in the Japanese than in the German
cohort. Only bowel and bladder FSS was higher in
the Japanese cohort. Also the EDSS increase per
attack showed a tendency to higher values in the
German cohort. Severe disability at last follow-up
defined as an EDSS 6 was similar in both cohorts
(Table 1).
Onset attack and relapses
The clinical presentation at disease onset was similar
in both cohorts (Table 2, Figure 3).
The median time to the second attack after the onset
attack was 0.65 years (IQR: 0.23-1.65) in the
German cohort and 1.21 years (IQR: 0.34-2.48) in
the Japanese cohort (p¼ 0.087) (Table 2). The
recovery from the first attack, the first ON and the
first myelitis was similar in both cohorts (Table 2).
Treatment
Acute attacks were mainly treated with intravenous
high-dose corticosteroids. In the German cohort,
escalation of therapy ensued in 23.8% of all attacks
after a first treatment course. Only one attack within
the Japanese cohort received escalation therapy.
Table 4 provides details about acute attack
treatment.
Only a minority of patients received preventive
treatment after the onset attack (German cohort:
n¼ 13 (34.2%), Japanese cohort: n¼ 16 (29.6%)).
The time between disease onset and start of first
continuous treatment was significantly longer in
the Japanese cohort (Median [IQR]¼2.34 years
[0.28-10.08]) than in the German cohort (Median
[IQR]¼0.55 years [0.15-1.88], p¼ 0.009). Of note,
four German patients had already received immuno-












Figure 1. Histogram for age at onset for both centers. The
histogram reveals two peaks of disease onset (1) around
20 years of age and (2) around 40 years of age.
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symptoms because of comorbidities. In these cases,
the time to first treatment was set to zero. Patients
from the Japanese cohort had on average more
attacks before first treatment (Median [IQR] ¼2.5
[1-7]) than German patients (Median [IQR] ¼2 [1-
3], p¼ 0.047).
Most patients were receiving continuous immuno-
therapy at last follow-up (German cohort: 89.5%,
Japanese cohort 92.6%, p¼ 0.883) (Figure 4/Table
3). While rituximab was the most commonly used
drug in the German cohort, it had not been pre-
scribed to any Japanese patient (p< 0.001)








Total number of attacks: median [IQR] 3.00 [2.00, 5.00] 5.00 [2.00, 9.75] 0.115
Optic neuritis: n (%) 24 (63.2%) 40 (74.1%) 0.373
Bilateral optic neuritis: n (%) 11 (28.9%) 22 (40.7%) 0.347
Myelitis: n (%) 34 (89.5%) 43 (79.6%) 0.331
Long spinal cord lesiona: n (%) 31 (86.1%) 36 (66.7%) 0.068
Brain attack (including area postrema,
brainstem and cerebral attacks): n (%)
6 (15.8%) 22 (40.7%) 0.020
Brainstem attack: n (%) 6 (15.8%) 12 (22.2%) 0.618
Area postrema attack: n (%) 2 (5.3%) 7 (13.0%) 0.386
Cerebral attack: n (%) 0 (0.0%) 9 (16.7%) 0.022
Annualized relapse rate: median [IQR] 0.50 [0.38, 0.70] 0.41 [0.31, 0.86] 0.403
Presentation at onset
Optic neuritis at onset: n (%) 18 (47.4%) 25 (46.3%) >0.999
Myelitis at onset: n (%) 18 (47.4%) 22 (40.7%) 0.676
Brain attack (including area postrema,
brainstem and cerebral attacks) at onset: n (%)
5 (13.2%) 11 (20.4%) 0.536
Area postrema attack at onset: n (%) 0 (0.0%) 5 (9.3%) 0.144
Brainstem attack at onset: n (%) 5 (13.2%) 5 (9.3%) 0.801
Cerebral attack at onset: n (%) 0 (0.0%) 1 (1.9%) >0.999
Presentation at second attack
Optic neuritis at second attack: n (%) 16 (42.1%) 22 (40.7%) >0.999
Myelitis at second attack: n (%) 20 (52.6%) 21 (38.9%) 0.274
Brain attack at second attack: n (%) 1 (2.6%) 4 (7.4%) 0.598
Recovery
First attack (any type) Full: n (%) 8 (25.8%) 7 (14.3) 0.229
Partial: n (%) 21 (67.7%) 41 (83.7%)
None: n (%) 2 (6.5%) 1 (2.0%)
First myelitis Full: n (%) 8 (25.8%) 9 (18.4%) 0.541
Partial: n (%) 17 (54.8%) 29 (59.2%)
None: n (%) 2 (6.5%) 1 (2.0%)
First optic neuritis Full: n (%) 6 (19.4%) 7 (14.3%) 0.497
Partial: n (%) 11 (35.5%) 26 (53.1%)
None: n (%) 2 (6.5%) 2 (4.1%)
AQP4-IgG: Aquaporin 4-immunoglobulin G; CSF: cerebro-spinal fluid; IQR: interquartile range; n: number;
NMOSD: neuromyelitis optica spectrum disorders; SD: standard deviation.
Note that these group comparisons were performed using Chi-Square test to compare categorial variables and
Wilcoxon-Mann-Whitney test for continuous variables. Please note, that Figure 3 provides details on the occurrence of
combined syndromes during the first attack. a) Lesion extension of 3 contiguous vertebral segments. Significant p-













(Table 3). In the Japanese cohort, in contrast, oral
prednisolone monotherapy was the most common
medication (Figure 4). Among Japanese patients
with oral prednisolone as mono- or add-on therapy,
49 out of 50 received a dose of 7.5mg per day,
while only 1 out of 6 German patients received a
dose of 7.5mg per day (p< 0.001). The frequency
of azathioprine was similar in both cohorts, though
in the Japanese cohort it was combined with contin-
uous prednisolone treatment (Figure 4). In both
groups there were no major changes in treatment
strategies over the disease course (Table 4). The
ARR before any treatment (Germany: Median
[IQR] ¼2.48 [1.10-5.37], Japan: 1.88 [0.58-6.97])
was higher compared to the ARR during treatment
at last follow-up (Germany: Median [IQR] ¼0.00
[0.00-0.20], Japan: 0.11 [0.00-0.29], p< 0.001) and
did not differ between the German and the Japanese
cohort (Table 3). Treatment duration and dosage of
the respective medication are given in Table 3.
MRI at last follow-up
MRI at last follow-up showed chronic myelitis
lesions in 26 patients (70.3%) from the German
cohort and in 33 patients (63.5%) from the
Japanese cohort (p¼ 0.658). Chronic area postrema
and/or brainstem lesions were present in 17 patients
(47.2%) from the German and in 15 patients
(27.8%) from the Japanese cohort. Chronic cerebral
lesions were more frequent in the German cohort
(n¼ 33 (89.2%) vs. n¼ 37 (68.5%, p¼ 0.041).
Discussion
This comparative study of German and Japanese
patients with AQP-IgG-positive NMOSD compared
commonalities and differences in demographics,
clinical presentation, disease course, autoimmune
comorbidities, and immunotherapy. Both cohorts
show the expected female predominance with a
female-to-male ratio of 11.7:1 in the German
cohort, and of 8:1 in the Japanese cohort.2 In con-
trast to previous data, where Japanese and Korean
patients had a younger age at disease onset, mean
age at disease onset was slightly above forty years in
both cohorts, as previously described in German
cohorts.13,18,24 Consequently, ethnicity alone does
Figure 2. Comparison of relapse risk in the German and
the Japanese cohorts. Kaplan–Meier plot with Cox
regression comparing show that there is no significant
difference in the risk for a relapse between both cohorts.
Please note that the analysis includes only patients with a
follow-up period of at least two years, and that patients























Figure 3. Type of onset attack in the German and the Japanese cohorts. The chart shows the respective type of onset
attacks. AP: area postrema syndrome; BS: brainstem syndrome; CB: cerebral syndrome; MY: myelitis; ON: optic neuritis.
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not predict the age of disease onset, which may
differ between different Asian populations.18
In line with the literature,2 the most frequent syn-
dromes at disease onset in the German and Japanese
cohorts were ON in 47% and 46%, and myelitis in
47% and 41%, respectively. Only 2% (Germany)
and 3% (Japan) of the patients exhibited an epony-
mous neuromyelitis optica syndrome with simulta-
neous myelitis and ON. Forty-one percent of
Japanese patients suffered from area postrema,
brainstem or cerebral symptoms. Brain attacks
during disease course occurred more frequently in
the Japanese cohort. Interestingly, MRI at last
follow-up showed more residual cerebral lesions in
the German cohort. This discrepancy is probably due
to different MRI tools (1.5-Tesla in Chiba vs. 3-
Tesla in Berlin) with higher resolution MRI showing
higher numbers of lesions. Of note, most cerebral
lesions were asymptomatic, unspecific white matter
lesions, which occur frequently in NMOSD.25
Differences between both cohorts mainly concerned
the degree of disability and long-term treatment







Currently treated: n (%) 34 (89.5%) 50 (92.6%) 0.883
Oral prednisolone: n (%) 6 (15.8%) 50 (92.6%) <0.001
Glatirameracetate: n (%) 1 (2.6%) 0 (0.0%) 0.859
Rituximab: n (%) 20 (52.6%) 0 (0.0%) <0.001
Azathioprine: n (%) 9 (23.7%) 12 (22.2%) >0.999
Tacrolimus: n (%) 0 (0.0%) 1 (1.9%) >0.999
Belimumab: n (%) 1 (2.6%) 0 (0.0%) 0.859
Mycophenolate mofetil: n (%) 1 (2.6%) 0 (0.0%) 0.859
Eculizumab: n (%) 0 (0.0%) 1 (1.9%) >0.999
Tocilizumab: n (%) 1 (2.6%) 0 (0.0%) 0.859
Cyclophosphamide: n (%) 1 (2.6%) 0 (0.0%) 0.859
Time on current treatment:
median in years [IQR]
4.48 [1.95, 5.70] 4.58 [2.13, 7.38] 0.517
Time on prednisolone monotherapy:
median in years [IQR]
– 5.22 [2.27, 8.18] –
Time on rituximab monotherapy:
median in years [IQR]
4.48 [1.50, 5.64] – –
Time on azathioprine monotherapy:
median in years [IQR]
6.53 [4.33, 7.32] –
Time on azathioprine plus prednisolone:
median in years [IQR]
20.27 [10.78, 29.76] –
Number of attacks during current
treatmenta: median [IQR]
0.00 [0.00, 1.00] 1.00 [0.00, 1.75] 0.273
ARR before any treatmenta:
median [IQR]
2.48 [1.10, 5.37] 1.88 [0.58, 6.97] 0.360
ARR on current treatmenta:
median [IQR]
0.00 [0.00, 0.20] 0.11 [0.00, 0.29] 0.242
AQP4-IgG: Aquaporin 4-immunoglobulin G; IQR: interquartile range; n: number; n.a.: not available; NMOSD:
neuromyelitis optica spectrum disorders.
Note that these group comparisons were performed using Chi-Square test for categorial variables and Wilcoxon-Mann-
Whitney test for continuous variables.aFor 31 patients from Germany and 46 patients from Japan with at least one year
of treatment duration at last follow-up; Dosage of oral prednisolone: 2mg–20mg/d, glatirameracetate: 20mg/d,
rituximab: 500-2000mg/6months, azathioprine: 50 to 150mg/d, tacrolimus 3mg/d, mycophenolate mofetil: 1500mg/




strategies, suggesting a lower disease activity in
Japanese than in German patients. Though the total
EDSS was similar in both cohorts, Japanese patients
had a longer disease duration at the time of assess-
ment and brainstem, cerebral, pyramidal, and senso-
ry FSS were lower than in German patients.
Moreover, the EDSS increase per attack showed a
tendency to higher values in the German cohort.
Only bowel and bladder FSS was higher in the
Japanese cohort. These findings confirm previous
data showing that Japanese patients have more fre-
quent brain manifestations than German patients but
in general less severe disability scores.13,18,19,25,26
In both cohorts, acute attacks were mainly treated with
intravenous high-dose corticosteroid therapy. Only a
small subset of attacks was treated with immunoad-
sorption therapy – more frequently used in the
Japanese cohort – and plasmapheresis – more frequent-
ly used in the German cohort. In German patients,
escalation of therapy ensued in 23.8% of all attacks
after a first treatment course, mainly with high-dose
corticosteroid therapy or intravenous immunoglobu-
lins. Only one attack in the Japanese cohort received
escalation therapy. This indicates again a higher attack
severity among German patients. The final degree of
recovery from relapses was similar in both cohorts.
In the Japanese cohort, relapses were more frequent
before the start of the first treatment. However, as
previously described in Japanese NMOSD
cohorts,13,18 the time between onset attack and first
treatment was about two years in the Japanese cohort
but significantly shorter – also compared with other
Caucasian cohorts18 – in the German cohort. These
findings support the hypothesis that Japanese
patients presenting with a brain-dominant disease
manifestation may have a better clinical prognosis
than German patients.27
An overall lower attack severity in the Japanese
cohort could explain the physicians’ choice for
slower treatment induction and less aggressive med-
ication. A more disabling attack severity in the
German cohort however, would necessitate an
early and more aggressive treatment induction, sim-
ilarly to what has been previously described.13 First
and current treatment differed considerably between
the two cohorts. At the time of assessment, most
Japanese patients were treated with oral predniso-
lone, often in high doses. In the German cohort, in
contrast, 50% of patients were treated with rituxi-
mab and 97.4% had a history of current or previous
immunosuppressive therapy. Rituximab is a mono-
clonal antibody against the CD20 molecule
expressed on B-lymphocytes. It has a significant
effect on disease activity and is one of the most
frequently used attack-preventive immunotherapies
for NMOSD in Europe.2 Currently there are no con-
trolled trials comparing the effect of long-time ther-
apy with oral corticosteroids and rituximab in
AQP4-IgG-positive NMOSD. Moreover, at the
time of assessment, no drug was approved for
the treatment on NMOSD and treatment
options have relied on off-label use and empiric
drugs with immunosuppressive and B-cell-depleting
effect (azathioprine, rituximab, tocilizumab etc.).28
Since then, the C5 complement inhibitor eculizu-
mab, the CD19 inhibitor inebilizumab and the
interleukin-6 receptor inhibitor satralizumab have




























Figure 4. Current treatment strategies in the German and Japanese cohorts. The chart shows the type of current med-
ication in the Japanese and German cohorts. AZA: azathioprine, monoclonal AB: monoclonal antibody, PSL: prednis-
olone, other includes cyclophosphamide (n¼ 1) and glatirameracetate (n¼ 1).
Multiple Sclerosis Journal-Experimental, Translational and Clinical
8 www.sagepub.com/msjetc
A different usage of immunotherapies is very likely
related to different reimbursement policies of
Japanese and German healthcare systems and
explains a higher bar in Japan than in Germany but
also compared to Korea24,31 to use rituximab as
off-label therapy. Recently, the efficacy of rituximab
in AQP4-IgG-positive NMOSD was confirmed in a
first randomized, double-blinded, placebo-controlled
Japanese trial (RIN-1).32 These results may affect
the practice of treating NMOSD in Japan. As there
have been few clinical trials for NMOSD to give
clear guidelines,2,33 there is an important need for
future multicenter studies.
In contrast to previous studies,13 the ARR was
similar in both cohorts. This is presumably the
consequence of early and effective immunotherapy
in the German cohort, reducing the relatively
higher disease activity. These results might be
biased as the German cohort is observed and treated
in a tertiary referral center for NMOSD.
Therefore, the treatment strategies in the German
cohort might not be representative of the average
German clinical practice. Still, the median EDSS
in both cohorts was above three, confirming the
rarity of benign NMOSD,34 despite early treatment
and significant reduction of the ARR under immu-
notherapy. These findings correspond to previous
data from a Korean cohort.24
NMOSD often coexists with other autoimmune dis-
eases, including most frequently thyroiditis,






Immunomodulatory therapy during the entire disease course
Ever treated: n (%) 37 (97.4%) 51 (94.4%) 0.874
Rituximab: n (%) 24 (63.2%) 0 (0.0%) <0.001
Azathioprine: n (%) 24 (63.2%) 14 (25.9%) 0.001
Cyclophosphamide: n (%) 4 (10.5%) 0 (0.0%) 0.055
Mitoxantron: n (%) 4 (10.5%) 0 (0.0%) 0.055
Tacrolimus: n (%) 0 (0.0%) 1 (1.9%) >0.999
Belimumab: n (%) 1 (2.6%) 0 (0.0%) 0.859
Cyclosporin A: n (%) 0 (0.0%) 2 (3.7%) 0.636
Mycophenolate mofetil: n (%) 1 (2.6%) 0 (0.0%) 0.859
Methotrexat: n (%) 1 (2.6%) 0 (0.0%) 0.859
Eculizumab: n (%) 0 (0.0%) 1 (1.9%) >0.999
Tocilizumab: n (%) 1 (2.6%) 0 (0.0%) 0.859
Attack treatment during the entire disease coursea
IVMP: n of attacks (%) 111 (85.4%) 311 (84.5%) 0.923
Plasmapheresis: n of attacks (%) 6 (4.6%) 6 (1.6%) 0.115
Immunoadsorption: n of attacks (%) 1 (0.8%) 29 (7.9%) 0.115
Intravenous immunoglobulins: n of attacks (%) 1 (0.8%) 1 (0.3%) >0.999
No treatment: n of attacks (%) 11 (8.5%) 21 (5.7%) 0.372
No information: n of attacks (%) 34 (20.7%) 18 (4.7%) <0.001
Escalation therapyb
Plasmapheresis: n of attacks (%) 10 (8.2%) 0 (0.0%) -
IVMP: n of attacks (%) 14 (11.5%) 0 (0.01%) -
Immunoadsorption: n of attacks (%) 2 (1.6%) 1 (0.0%) -
Intravenous immunoglobulines: n of attacks (%) 3 (2.5%) 0 (0.0%) -
AQP4-IgG: Aquaporin 4-immunoglobulin G; n: number; NMOSD: neuromyelitis optica spectrum disorders.
Note that these group comparisons were performed using Chi-Square test. Significant p-values are indicated in bold.
aAttack treatment information was available for 498 out of 550 attacks, 130 attacks in the German cohort and 368
attacks in the Japanese cohort, respectively.
bDue to the small numbers no p-values are provided for escalation therapy.
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myasthenia gravis, SLE and Sjogren’s syn-
drome.35,36 Interestingly, SLE was the most frequent
autoimmune comorbidity in the German cohort, but
was not reported in the Japanese cohort. This is in
contrast to the general population, where SLE has a
higher incidence in Asia than in Europe.37 This var-
iation could reflect differences in the genetic back-
ground of affected patients with a higher
susceptibility to concomitant autoimmune diseases
in German NMOSD patients. In line with a previous
study on NMOSD in Japanese patients,27 Sjogren’s
Syndrome was the most frequent autoimmune
comorbidity in the Japanese cohort. In general, auto-
immune comorbidities occurred considerably more
often in the German cohort and the frequency in the
Japanese cohort was similar than previously reported
in Korean patients with AQP4-autoimmunity.24
The main limitations of our study are the retrospec-
tive design and, due to the rarity of AQP4-IgG-
positive NMOSD, the relatively small number of
patients. Unfortunately, our data do not allow any
conclusion about the incidence of AQP4-IgG-
positive NMOSD in Germany and Japan: First
study participation was voluntary in both centers.
Second, the Berlin cohort included patients from
all over Germany, but the center is not the only
referral center in the country. The Chiba cohort
included mainly patients who lived in Chiba
Prefecture. The assay method for anti-AQP4-IgG
was different between both cohorts and a more con-
sistent detection method may lead to more accurate
diagnosis of antibody serostatus, although the high
specificity and sensitivity of both had been previous-
ly well established.23 Further, MRI results are based
on written reports, were not centrally reviewed and
may include inter-rater discrepancies. Additionally,
the interval between the onset of clinical symptoms
and the MRI can influence the MRI-presentation of
LETM lesions, which could not be controlled for in
the retrospective study design. As all data were
acquired outside of acute attacks, no Gadolinium-
based contrast agent was administered. Therefore,
we were unable to adjudicate whether clinical
attacks were accompanied by Gadolinium-
enhancing lesions on MRI.
The main strengths of our study are the well-defined
patient samples of Caucasian and East-Asian ethnic-
ity, enabling us to question whether clinical differ-
ences are due to treatment effects.
In conclusion, we show that patients from the
Japanese cohort have more brain attacks, less
autoimmune comorbidities, and lower brainstem,
cerebral, pyramidal, and sensory FSS than German
patients. Conversely, German patients received
immunotherapies earlier and more frequently. This
may result in a similar presentation of overall disease
activity and relapse rate despite a presumably higher
underlying disease activity in the German cohort.
Further research is necessary to clarify why Asian
patients have more frequent brain attacks.
Moreover, our findings emphasize the necessity for
prospective, international multicenter studies in order
to evaluate the efficacy of the respective medication
and to develop optimized treatment guidelines for
AQP4-IgG-positive NMOSD with regard to the
patients’ ethnicity. The data presented here might
help design future interventional clinical trials and
treatment guidelines that should take the ethnicity of
patients with NMOSD into consideration.
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